Zenas Biopharma Inc’s filing revealed that its Director Nunn Jason Raleigh acquired Company’s shares for reported $1.2 million on Oct 09 ’25. In the deal valued at $19.00 per share,63,158 shares were bought. As a result of this transaction, Nunn Jason Raleigh now holds 1,173,395 shares worth roughly $38.24 million.
Then, SR ONE CAPITAL MANAGEMENT, LLC bought 126,315 shares, generating $2,399,985 in total proceeds. Upon buying the shares at $19.00, the 10% Owner now owns 1,917,895 shares.
Before that, ENRIGHT PATRICK G bought 105,265 shares. Zenas Biopharma Inc shares valued at $2,000,035 were divested by the Director at a price of $19.00 per share. As a result of the transaction, ENRIGHT PATRICK G now holds 1,832,669 shares, worth roughly $59.73 million.
Wedbush initiated its Zenas Biopharma Inc [ZBIO] rating to an Outperform in a research note published on March 20, 2025; the price target was $35. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in early February with a ‘”an Outperform”‘ rating. H.C. Wainwright began covering ZBIO with “Buy” recommendation on December 16, 2024. Rodman & Renshaw started covering the stock on November 05, 2024. It rated ZBIO as “a Buy”.
Price Performance Review of ZBIO
On Monday, Zenas Biopharma Inc [NASDAQ:ZBIO] saw its stock fall -19.71% to $32.59. Over the last five days, the stock has lost -17.21%. Zenas Biopharma Inc shares have risen nearly 255.79% since the year began. Nevertheless, the stocks have risen 297.92% over the past one year. While a 52-week high of $41.50 was reached on 12/08/25, a 52-week low of $5.83 was recorded on 01/28/25.
Levels Of Support And Resistance For ZBIO Stock
The 24-hour chart illustrates a support level at 29.03, which if violated will result in even more drops to 25.48. On the upside, there is a resistance level at 38.62. A further resistance level may holdings at 44.66.
How much short interest is there in Zenas Biopharma Inc?
A steep rise in short interest was recorded in Zenas Biopharma Inc stocks on 2025-11-28, growing by 92060.0 shares to a total of 4.86 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 4.77 million shares. There was a rise of 1.89%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 08, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $40 price target.
